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Simple Summary: Hyperthermia was proven to enhance the efficacy of chemo- and radiation ther-
apy treatment of glioblastoma multiforme, an aggressive brain tumor of poor prognosis. Despite
good clinical results in other tumor types and locations, hyperthermia induced by electromagnetic
waves in the radiofrequency range is not available so far for the treatment of brain tumors due to
the highly sensitive surrounding tissue and lack of non-invasive therapy monitoring. ThermalMR
integrates non-invasive diagnosis, therapy, and therapy monitoring in a single RF applicator device
by employing radiowaves for magnetic resonance imaging, radiofrequency heating, as well as mag-
netic resonance thermometry. This work examines three optimization algorithms for hyperthermia
treatment planning and up to ten RF applicator configurations for a cohort of nine patient models
with glioblastoma multiforme. Clinical diversity is represented in target size and location and the
inclusion of post-operative models. Our findings indicate the need and potential for patient-specific
treatment planning and RF applicator design when targeting brain tumors.
Abstract: Thermal intervention is a potent sensitizer of cells to chemo- and radiotherapy in cancer
treatment. Glioblastoma multiforme (GBM) is a potential clinical target, given the cancer’s aggressive
nature and resistance to current treatment options. This drives research into optimization algorithms
for treatment planning as well as radiofrequency (RF) applicator design for treatment delivery. In this
work, nine clinically realistic GBM target volumes (TVs) for thermal intervention are compared using
three optimization algorithms and up to ten RF applicator designs for thermal magnetic resonance.
Hyperthermia treatment planning (HTP) was successfully performed for all cases, including very
small, large, and even split target volumes. Minimum requirements formulated for the metrics
assessing HTP outcome were met and exceeded for all patient specific cases. Results indicate a
16 channel two row arrangement to be most promising. HTP of TVs with a small extent in the
cranial–caudal direction in conjunction with a large radial extent remains challenging despite the
advanced optimization algorithms used. In general, deep seated targets are favorable. Overall,
our findings indicate that a one-size-fits-all RF applicator might not be the ultimate approach in
hyperthermia of brain tumors. It stands to reason that modular and reconfigurable RF applicator
configurations might best suit the needs of targeting individual GBM geometry.
Keywords: thermal magnetic resonance; radiofrequency hyperthermia; patient-specific therapy
planning; EMF simulations; RF applicator; glioblastoma multiforme
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1. Introduction
Glioblastoma multiforme (GBM) is the most aggressive type of cancer and is still
considered to be incurable. For GBM treatment, multimodal approaches including surgery
and chemo- and radiation therapy in conjunction with adjunct hyperthermia therapy (HT)
have proven to be of clinical benefit [1]. HT of various tumor types and locations using
low (8–13.56 MHz), intermediate (70–100 MHz), or high (433 MHz) radio- frequencies
(RFs) has culminated in a body of literature documenting the benefit of thermal interven-
tion for boosting the efficacy of chemo- and radiation therapy [2–8]. Notwithstanding
the encouraging results obtained for GBM treatment with interstitial hyperthermia [1],
research into a less invasive approach is needed. These explorations include thermo-
ablation via transcranial magnetic resonance (MR)-guided focused ultrasound, which
demonstrated superb focal quality but limited ability to cover large target volumes [9–11].
Other approaches take advantage of modulated capacitive hyperthermia [12], which is
constrained by insufficient specific absorption rates (SAR) and limited focusing in deep
seated target regions [13,14]. Deep RF induced hyperthermia of GBM presents an alter-
native direction. Recent developments have reported on RF hyperthermia of GBM using
fixed frequencies (f = 297 MHz [15,16], f = 915 MHz [17]) or multiple frequencies [18,19].
Magnetic nanoparticle heating has also shown promising results as localized adjuvant
therapy [20,21]. All of these techniques can help to boost treatment efficacy by enhancing
the permeability of the blood–brain–barrier for drugs or nanoparticles used in a combined
treatment regime [22–24], with the most intriguing combination being the use of thermore-
sponsive carriers releasing the drugs only in the heating target site, allowing for a reduction
of systemic side effects [25,26]. For the latter as well as for RF hyperthermia treatments in
the brain, control over the RF power deposition in magnitude and spatial distribution is
essential [27].
Taken together, this has stimulated the development of RF hardware including multi-
channel signal generators and RF applicators tailored for HT of the brain [15,16,27–29].
Typical RF hyperthermia devices are annular-phased-arrays (APA) with the steer- abil-
ity of the RF field depending on the number of independent transmit channels [2,15,30].
Arranging the antennae in multiple rings in the cranial–caudal direction increases the
focusing capabilities of the RF array [16,31,32]. Moreover, HT planning (HTP) procedures
have been advanced using numerical approaches, including field shaping optimization
algorithms [19,33,34]. A number of algorithms has been investigated, differing in con-
straints and targets used for optimization. Some algorithms target the global RF power
deposition [33], optimize the dominant component of the electric (E-) field [34], use virtual
observation points (VOPs) to accelerate the optimization [16], or compute an optimum fit
to a given target RF power distribution using one or multiple RF frequencies [19]. These
hardware and software developments are of relevance for brain tumor HT, where a rig-
orous confinement of high RF exposure levels to the target volume (TV) is essential. To
enable efficient and safe RF power deposition, fulfillment of physical, engineering, and
computational requirements is of the essence. Ensuring a patient and problem-oriented
adaptation of the size, uniformity, and location of the RF energy de- position in the brain
target region is highly relevant for HT, with the focal point quality being governed by
the radiation pattern of the single RF transmit element, the RF channel count, antenna
positioning and arrangement, and by the thermal intervention radio- frequency of the RF
applicator. Assuming a brain matter ratio of approximately 40% white matter and 60%
grey matter, f = 297 MHz results in a wavelength of ~14 cm and in a minimum achievable
hotspot size of ~4.5 cm. This is in the range of realistic brain tumor TVs [35,36], which
deems 297 MHz to be suitable for HT of GBM.
Dipole antenna building blocks are of proven value for HT applicators [15,16,18,
28,31,37–39]. If assembled in APA, the long dipole axis is arranged in the cranial–caudal
direction to maximize the component of the incident electric field, reaching the body surface
tangentially to minimize superficial RF power deposition. This coincides with the dipole
arrangement used for magnetic resonance imaging (MRI), where the magnetic component
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of the incident EM field is required to be perpendicular to the static magnetic field of the MR
scanner, which is aligned in the cranial–caudal direction. Using an operational frequency
of 297 MHz suits the physical requirements for RF focusing and matches the operational
frequency of MRI at 7 Tesla. Thermal magnetic resonance (ThermalMR) is an HT variant
that integrates RF-induced heating [16,27,39–41], in vivo temperature mapping using MR
thermometry (MRT) for temperature dose and therapy control [27,42–44], anatomic and
functional MRI for diagnosis and patient positioning, and the option for x-nuclei MRI
in a single, multi-purpose RF applicator permitting supervised targeted temperature
modulation [15,16,45].
GBM size and geometries range from small TVs challenging the focusing capabilities
of an RF applicator as well as the field shaping algorithm to large TVs requiring a uni-
form distribution of RF energy in regions whose dimensions can reach a full wavelength.
Notwithstanding the broad spectrum of patient specific GBM size and geometry, a sharp
decline of RF exposure at the interface to surrounding healthy tissues is a key requirement
for HTP. Recognizing the engineering challenges and the clinical context, this work exam-
ines the efficacy of RF field shaping for brain HT in nine clinically diverse GBM TVs. For
this purpose, electromagnetic field (EMF) simulations that incorporate models based on
clinical data obtained from computed tomography scans of GBM patients are performed.
Three RF field shaping algorithms are applied to assess the performance of up to ten dipole
building block-based RF applicator designs per patient model. For quantitative analysis,
five metrics including (i) the maximum specific absorption rate averaged over 10 g tissue
(SAR10g) in the TV, (ii) the SAR amplification factor (SAF), (iii) the relative target coverage
where the RF power deposition exposure level exceeds the limit set for healthy tissue, (iv)
the target-to-hotspot quotient (THQ) and (v) the volumetric power density in the TV are
used. These (metrics) will be examined to identify the most successful HTP algorithm and
RF applicator design. We hypothesize that the VOP-based power optimization outperforms
the VOP-based uniformity optimization for RF field shaping [16], and that the iterative
multiplexed vector field shaping (MVFS) approach provides a higher accuracy than the
VOP-based approaches. We also expect the planar RF applicator configurations to yield
modest HTP results while the high density RF applicators with a high channel count might
not show improvement against RF applicators with lower channel count but the same head
coverage. After testing our hypotheses we will draw conclusions on predictors of HTP
outcome based on GBM target size and location.
2. Materials and Methods
2.1. Patient Voxel Models
One aim of this study was to assess the feasibility of our HTP workflow [16] in a larger
and more diverse set of clinical TVs. For this purpose, nine patient data sets (Pat Model 1–9)
were selected for the creation of human voxel models used for EMF simulations [46]. Upon
selection, we aimed for a high diversity in TV size and location, often favoring models
deemed more challenging for successful treatment. The most challenging cases included
very large TVs (Pat Model 1 and 8), small and superficial TVs (Pat Model 2 and 4), TVs
with a small extent in the cranial–caudal direction (i.e., along the long axis of the dipole
antenna; Pat Model 4), and even a model with two separate small TVs (Pat Model 5). To
further broaden the representation of the clinical GBM spectrum, two patient models (Pat
Model 2 and 6) were based on the postoperative CT scans of patients whose tumor was
deemed operable. For these cases, the core of the TV did not consist of solid, macroscopic
tumor tissue but a resection cavity filled with blood. Figure 1 illustrates all nine patient
models using slices positioned at the greatest extent of the target volume together with
their volume, bounding box size (i.e., maximum extent in all three dimensions) and the
total mass of the simulated model.
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Figure 1. Nine head voxel models were generated based on clinical CT data derived from glioblastoma multiforme 
(GBM) patients. Each model is depicted in sagittal, coronal, and axial view with the slice positioned at the greatest extent 
of the target volume. The volume and the bounding box size are indicated for each patient model. The brain was homo-
geneously modeled (grey) and assigned the resulting dielectric properties (40% white matter + 60% grey matter; σ (avg 
brain) = 0.52 S/m, εr (avg brain) = 50.3). The macroscopic tumor mass (dark orange) was assigned σ (tumor) = 1.15 S/m, εr 
(tumor) = 66.5 [47]; the resection cavity (black) was assigned dielectric properties of blood (σ (blood) = 1.32 S/m, εr (blood) 
= 65.7); the clinical target volume surrounding the tumor (light orange) was assigned dielectric properties of the brain. 
The latter together with either the gross tumor volume or the resection cavity form the target volume for patient-specific 
hyperthermia treatment planning (HTP). In Pat Model 4, the tilting of the head results in the axial slice at the largest ex-
tent of the clinical target volume (CTV) to coincide with the CSF surrounding the frontal lobe of the brain. What looks like 
a seemingly disconnected spot of CSF behind the eyes is in fact a continuous layer to the slice above. 
Most organs and tissues were delineated for all patient models, while some specific 
organs at risk were selected based on the individual location of the target volume (see 
Appendix A). Three-dimensional voxel models with the resolution of the underlying CT 
scan were generated using a previously developed workflow [46]. Large ventricles filled 
with highly conductive cerebrospinal fluid (CSF, σ = 2.22 S/m [48,49]) were easily seg-
mented from the organs at risk. Delineating the thin outer CSF layer surrounding the 
brain is more challenging, yet of importance to address the potential shielding effect by 
the closed layer. To address this challenge, we created this layer in the simulation model 
by recreating the shape of the brain with an isotropic size increase of 5%. The resulting 
layer was assigned dielectric properties of CSF and set to overwrite the adjacent 
fat/muscle/bone structure of the skull. For a full list of delineated organs, please refer to 
Appendix A. 
2.2. Radiofrequency Applicators and Electromagnetic Field Simulations 
The RF applicators used in this study were comprised of bow tie dipole antennae 
submerged in a high permittivity medium for wavelength and thus dipole length short-
ening. Heavy water (εr ≈ 81) [15] and a ceramic slurry (εr ≈ 200) [16] can be used to govern 
the size of the resulting building block and thus the number of independent channels 
being azimuthally arranged around the head. The RF applicator configurations differ in 
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The latt r together with either the gross tumor volume or the resecti n cavity form the target volume for patient-specific
hypertherm a trea men planning (HTP). In Pat Model 4, the tilting of the head r sults in the axial slice at the l rgest extent
of the clinical target volume (CTV) to coincide with the CSF surrounding the frontal lobe of the brain. What looks like a
seemingly disconnected spot of CSF behind the eyes is in fact a continuous layer to the slice above.
Most organs and tissues were delineate for all patient m dels, whil some specific
organs at risk wer selected based on the individual locati n of the target volume (see
Appendix A). Three-dimensional voxel models with the resolution of the underlying
CT scan were generated using a previo sly developed workflow [46]. Large ventricles
filled with highly conductive cerebrospinal fluid (CSF, σ = 2.22 S/m [48,49]) were easily
segmented from the organs at risk. Delineating the thin outer CSF layer surrounding the
brain is more challenging, yet of importance to address the potential shielding effect by the
closed layer. To address this challenge, we created this layer in the simulation model by
recreating the shape of the brain with an isotropic size increase of 5%. The resulting layer
was assigned dielectric properties of CSF and set to overwrite the adjacent fat/muscle/bone
structure of the skull. For a full list of delineated organs, please refer to Appendix A.
2.2. Radiofrequency Applicators and Electromagnetic Field Simulations
The RF applicators used in this study were comprised of bow tie dipole antennae
submerged in a high permittivity medium for wavelength and thus dipole length shorten-
ing. Heavy water (εr ≈ 81) [15] and a ceramic slurry (εr ≈ 200) [16] can be used to govern
the size of the resulting building block and thus the number of independent channels
being azimuthally arranged around the head. The RF applicator configurations differ in (i)
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number of independent transmit channels, (ii) coverage of the head in the cranial–caudal
direction, (iii) azimuthal arrangement, and (iv) the presence/absence of a water bolus:
(i) The number of independent transmit channels was increased from 8 to 16 to 32.
In the denomination of the RF applicators, this is represented at the first position:
8.*/16.*/32.*.
(ii) For the eight and 16 element arrays, the coverage in the cranial–caudal direction was
increased in three steps and was encoded in the second position of the RF applicator
denomination. Starting in a planar arrangement (*.P.*), first every second element
was displaced by half the length of the dipole to obtain an interleaved arrangement
(*.I.*), followed by shifting them by the full length of the RF antenna building block to
form a two-row arrangement (*.2R.*).
(iii) For every RF applicator configuration of (i) and (ii), the influence of arranging the
dipole building blocks in a ring (*.*.R; d = 240 mm) around the head versus an elliptical
arrangement with the same circumference but better conformity to the human head
(*.*.E; a1 = 220 mm, a2 = 260 mm) was investigated.
(iv) Adding a water bolus between the RF applicator and the patient’s body increases RF
coupling and can serve to adjust/decrease the surface temperature [50]. The presence
of a water bolus (*.WB) was tested for its influence on the treatment planning outcome
for the interleaved arrays 16.I.*.WB.
All RF applicator configurations are summarized in Figure 2.
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The extensive EMF simulations of the 32 channel high density RF applicator designs
were limited to the first three patient models, aiming at confirming our hypothesis that the
improvement in HTP vs. the 16 channel RF applicators does not outweigh the doubled
computational, engineering, and manufacturing effort [16]. Similarly, simulations of a
water bolus were limited to the more promising ergonomic design 16.I.E.WB for five patient
models.
For EMF simulations, the head voxel models were placed in the RF applicator with
the center of the TV aligning with the center of the RF applicator in the cranial–caudal
direction. In the other two dimensions, the head model was centered in the applicator.
All healthy organs were assigned dielectric properties, as listed in the IT’IS database [49].
Solid tumor tissue was assigned σ = 1.15 S/m and εr = 66.5, the average of two values
reported from the only in vivo measurement known to the authors [47]. The clinical target
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volume (CTV) around the macroscopic tumor growth was assigned dielectric properties
of healthy brain tissue (σavg brain = 0.52 S/m) due to unknown properties of microscopi-
cally infiltrated tissue. Additionally, no further information was available on the potential
presence of edema in the CTV. In both cases, the assigned electric conductivity was lower
than what could be suspected (σCSF = 2.22 S/m, σblood = 1.32 S/m, σtumor = 1.15 S/m).
The calculated power deposition would thus potentially be underestimating the real SAR,
making this a lower bound approach to the matter. With promising HTP results, this could
indicate an even better treatment realization, should the real electric conductivity be higher
than considered here. The same is true for the modeling of the resection cavity in Pat
Models 2 and 6, were dielectric properties of blood are assumed, consisting of a lower
bound approach to a potential mix of blood and CSF in the post-operative cavity. For a full
list of delineated organs and assigned dielectric properties, please refer to Appendix A.
EMF simulations of the patient model + RF applicator configuration were performed
for each individual transmit channel using Sim4Life V3.4 (ZurichMedTech, Zurich, Switzer-
land). Resolving the triangular shape of the dipoles (requires high resolution) yet main-
taining a reasonable computation time (favors a low resolution) led to highly anisotropic
gridding throughout the simulation volume. A minimal resolution of 3 × 3 × 3 mm3 was
maintained within the brain. The results were exported for further processing in MATLAB
(The MathWorks, Natick, MA, USA).
2.3. Hyperthermia Treatment Planning
From the channel-wise E-field data, the specific absorption rate was calculated, isotrop-
ically rebinned to a 3 × 3 × 3 mm3 resolution and finally averaged over 10 g of tissue
(SAR10g) [51]. Our approach of ThermalMR includes HTP and MR imaging, and the 10 g
averaging mass was thus chosen to address the requirements of RF hyperthermia and of
MRI, where SAR10g is used to monitor safe RF exposure limits in healthy tissue [52]. The
SAR averaging was implemented using a previously described algorithm [53] to ensure
that formulations violating the conservation of energy are not introduced. The power
balance for all simulations was assessed as a standard QA precaution based on the for-
malism introduced in [54], and the worst-case power imbalance was within the bound-
aries expected by the FDTD method. A good correlation of this averaging mass with
temperature rise was reported for RF hyperthermia treatment of a human subject [55] in
the head [56,57] and for the employed frequency range [51,58].
Based on SAR10g data, patient-specific hyperthermia treatment planning was per-
formed. For this purpose, our established optimization algorithms were employed to solve
the problem in the semidefinite relaxation approximation of quadratic form maximiza-
tion [16] using VOPs [59] to decrease computation time. Two approaches were used to
either (i) directly maximize the total power delivered to the TV (VOP power optimiza-
tion), or (ii) to address the homogeneity of the resulting RF power deposition in the TV as
a second optimization goal (VOP uniformity optimization).
The use of VOPs decreased the computation time of the actual optimization. Com-
puting the VOPs turned out to be the most time-consuming step in the post-processing.
Additionally, VOP compression inherently requires a certain overestimation of the local
SAR10g data [59], which can only partly be removed by rescaling the field data after opti-
mization. For these two reasons, the multiplexed vector field shaping (MVFS) approach
was implemented in a second step, enabling a higher accuracy due to the use of the full SAR
data and a shorter overall computation time enabled by its iterative approach [19]. Mathe-
matically speaking, the VOP-based algorithms are special cases of the MVFS optimization
problem using different constraints and targets to solve the problem, as summarized in
Figure 3.
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of hundreds of dipoles arranged equidistantly around the head serves as a benchmark
for HTP results. For deep seated targets, the best SAF reported at 298 MHz was 8.4.
Please note that the SAF metric normalizes to the remaining healthy tissue as a whole
without enforcing a limit on the local exposure. It is thus to be expected that this value
cannot be reproduced for larger TVs, where the ratio between TV and healthy tissue is
increased. It is calculated as SAF = SAR10g,mean(TV)/SAR10g,mean(healthy).
• The relative target coverage where the power deposition exposure level exceeds the
limit set for the healthy tissue TCSAR>Lim is a measure of the RF energy distribution
within the TV. Since this in an investigative metric to judge our HTP outcome, no
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minimum requirement can be formulated yet. It is quantified as TCSAR>Lim = VTV(SAR
> SARlim)/VTV.
• The target-to-hotspot quotient THQ [61] assesses local RF power deposition maxima
in healthy tissue by correlating the average power deposition in the TV to the first
volumetric percentile of local SAR10g exposure in healthy tissue. We were the first
to report a THQ > 1 in HTP of brain tumors [16,62]. THQ is calculated as THQ =
SAR10g,mean(TV)/P1,mean(SAR10g(healthy)).
• The volumetric power density in the TV PTV/VTV as a relative measure ensures the
comparability of the results between different TVs and might help to differentiate TVs
with a good treatment perspective from others. It relates the total power deposited
in the TV PTV to its volume VTV. This metric is particularly important, since the
deposited power PTV is driving the RF heating in the TV. Relating it to VTV makes it
comparable between patient models. For an approximated average tissue density of 1
g/cm3, this metric corresponds to the mean SAR in the TV. We hope that a PTV/VTV >
30 W/L is the minimum we can achieve.
We did not include TC25% [61,63,64] commonly used for superficial tumors because
our previous studies revealed a TC25% > 75% in all HTP results [16], which does not add
value to the current evaluation.
3. Results
3.1. Optimization Algorithm Comparison
First we compared the two VOP-based optimization algorithms for all patient models.
Figure 4 depicts the optimization results for all possible configurations. All metrics were
patient-wise normalized to the respective maximum across all algorithms (“inter-algorithm
maximum”) and across all arrays (“inter-array maximum”) and plotted as radar plots, i.e.,
the better the optimization result, the further out the line will cross the axes. The optimal
result would conform to the circumference of the plot.
Figure 4 suggests that the VOP power optimization (red) is always equal or superior to
the VOP uniformity optimization (blue). In most cases, this is true for all metrics including
the target coverage (TCSAR>Lim), indicating that trying to optimize the worst-case deviation
from the target is an unsuitable optimization goal. VOP uniformity optimization was thus
not further considered.
The plots also indicate that HTP using the MVFS algorithm (Figure 4, black lines)
outperformed the VOP-based optimization algorithms. The only exception was Pat Model
9, where the VOP power optimization was competitive with the MVFS optimization.
Interestingly, in all patient models, the SAF of the MVFS optimization underperformed
compared to the VOP power optimization results. This is not as surprising, as only
local SAR but not total absorbed RF power inside healthy tissues (i.e., global SAR) was
constrained in any of the approaches. The MVFS algorithm managed to supply additional
power to the target region at the expense of a higher average power density in healthy
tissues, as it was more efficient in exploiting power deposition in healthy tissue just below
the local SAR threshold of 40 W/kg. Given that all optimization algorithms use the same
constrained safe local RF exposure limit in healthy tissue, this is considered negligible
considering the significant improvement obtained for all other metrics. If desired, total
power deposition inside healthy tissues could be included in the constraints as well. From
here on, we thus focused on the MVFS algorithm.
Table 1 summarizes the largest value achieved for each metric and patient model and
outlines which RF applicator design and optimization algorithm was used. For each of the
listed optimization result, the number of excitations resulting from the HTP is indicated.
These phase and amplitude settings are to be executed in a time-interleaved manner for
the same duration (i.e., two excitation vectors = half the treatment time for each phase
and amplitude excitation setting). By fast switching between the excitation settings, the
cumulative exposure then results in their averaged SAR pattern, as obtained by the HTP.
While the most favorable RF applicator design changed throughout the patient models
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as well as the metrics in comparison, the MVFS optimization outperformed the other
optimization algorithms for all patients and metrics except the SAF, where the VOP power
optimization yielded the best results. For most of the best results found with the MVFS
optimization, a combination of two excitations was found sufficient for highly targeted RF
exposure. Only for Pat Models 5 and 9 was a set of three excitation patterns more successful.
Especially for the first, this is easily understandable given the challenging geometry of the
split TV. The best SAF results obtained using the VOP power optimization required just
one excitation. For the full results, please refer to the Supplementary Materials.




Figure 4. Comparison of all hyperthermia treatment planning results contrasted by optimization algorithm: red—VOP 
power optimization, blue—VOP uniformity optimization, black—MVFS optimization. All metrics are normalized to the 
respective inter-algorithm, inter-array maximum for each patient model. 
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outperformed the VOP-based optimization algorithms. The only exception was Pat 
Model 9, where the VOP power optimization was competitive with the MVFS optimiza-
tion. Interestingly, in all patient models, the SAF of the MVFS optimization underper-
formed compared to the VOP power optimization results. This is not as surprising, as 
only local SAR but not total absorbed RF power inside healthy tissues (i.e., global SAR) 
was constrained in any of the approaches. The MVFS algorithm managed to supply ad-
ditional power to the target region at the expense of a higher average power density in 
healthy tissues, as it was more efficient in exploiting power deposition in healthy tissue 
just below the local SAR threshold of 40 W/kg. Given that all optimization algorithms use 
the same constrained safe local RF exposure limit in healthy tissue, this is considered 
negligible considering the significant improvement obtained for all other metrics. If de-
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Table 1. Summary of the highest values achieved for each patient model and metric together with the RF applicator design,
optimization algorithm used, and number of excitations to yield the calculated RF exposure patterns by time-interleaved
application. The overall maxima are highlighted in green italic. For the full table of HTP results, please refer to the
Supplementary Materials.
Patient Model Metric Highest Value Design Algorithm Number ofExcitations
Pat Model 1
(V = 500 mL)
SAR10g,max (W/kg) 134.2 16.2R.E MVFS optimization 2
SAF 3.8 16.I.E.WB VOP power optimization 1
TCSAR>Lim (%) 83.5 16.2R.R MVFS optimization 2
THQ 1.5 16.2R.E = 32.2R.E MVFS optimization 2/3
PTV/VTV (W/L) 66.8 16.2R.E MVFS optimization 2
Pat Model 2
(V = 127 mL)
SAR10g,max (W/kg) 117.5 32.2R.E MVFS optimization 2
SAF 4.3 16.I.E.WB VOP power optimization 1
TCSAR>Lim (%) 84 32.2R.R MVFS optimization 2
THQ 1.4 32.2R.E MVFS optimization 2
PTV/VTV (W/L) 40 32.2R.E MVFS optimization 2
Pat Model 3
(V = 172 mL)
SAR10g,max (W/kg) 114.4 32.2R.R MVFS optimization 2
SAF 3.5 16.I.E.WB VOP power optimization 1
TCSAR>Lim (%) 96.9 32.2R.R MVFS optimization 2
THQ 1.5 32.2R.R MVFS optimization 2
PTV/VTV (W/L) 53.1 32.2R.R MVFS optimization 2
Pat Model 4
(V = 120 mL)
SAR10g,max (W/kg) 66.9 16.2R.E MVFS optimization 2
SAF 3.2 16.I.E.WB VOP power optimization 1
TCSAR>Lim (%) 50.8 16.2R.E MVFS optimization 2
THQ 1.1 16.2R.E MVFS optimization 2
PTV/VTV (W/L) 37.4 16.2R.E MVFS optimization 2
Pat Model 5
(V = 117 + 38 mL)
SAR10g,max (W/kg) 86.1 16.2R.R MVFS optimization 3
SAF 5.2 16.I.E.WB VOP power optimization 1
TCSAR>Lim (%) 76.5 16.2R.R MVFS optimization 3
THQ 1.3 16.2R.R MVFS optimization 3
PTV/VTV (W/L) 47.7 16.2R.R MVFS optimization 3
Pat Model 6
(V = 179 mL)
SAR10g,max (W/kg) 143.9 16.2R.R MVFS optimization 2
SAF 5.8 16.2R.R VOP power optimization 1
TCSAR>Lim (%) 83.1 16.I.E MVFS optimization 2
THQ 1.6 16.2R.R MVFS optimization 2
PTV/VTV (W/L) 56.8 16.2R.R MVFS optimization 2
Pat Model 7
(V = 151 mL)
SAR10g,max (W/kg) 114.3 16.2R.E MVFS optimization 2
SAF 4.9 16.2R.E VOP power optimization 1
TCSAR>Lim (%) 95.8 16.2R.E MVFS optimization 2
THQ 1.6 16.2R.E MVFS optimization 2
PTV/VTV (W/L) 52.8 16.2R.E MVFS optimization 2
Pat Model 8
(V = 400 mL)
SAR10g,max (W/kg) 115.8 16.2R.R MVFS optimization 2
SAF 2.9 16.I.R VOP power optimization 2
TCSAR>Lim (%) 63.1 16.2R.R MVFS optimization 2
THQ 1.2 16.2R.R MVFS optimization 2
PTV/VTV (W/L) 41 16.2R.R MVFS optimization 2
Pat Model 9
(V = 288 mL)
SAR10g,max (W/kg) 99.7 16.2R.E MVFS optimization 3
SAF 2.7 16.2R.E VOP power optimization 3
TCSAR>Lim (%) 69.3 16.2R.R MVFS optimization 3
THQ 1.3 16.2R.E MVFS optimization 3
PTV/VTV (W/L) 49.1 16.2R.E MVFS optimization 3
For each metric, we calculated the mean, standard deviation, and median of the best
results possible with our RF applicators and optimization algorithms to relate them to
our HTP aims: SAR10g,max = (110.3 ± 22.1) W/kg, median = 114.4 W/kg; SAF = 4.0 ± 1.0,
median = 3.8; TCSAR>Lim = (78.1 ± 14.2)%, median = 83.1%; THQ = 1.4 ± 0.2, median =
1.4 > 1; PTV/VTV = (49.4 ± 8.7) W/L, median = 49.1 W/L >> 30 W/L. Since these data
contain clinically unrealistic combinations of multiple RF applicators and/or optimization
algorithms for the same patient model, we repeated the same analysis for one configuration,
choosing the RF applicator and optimization algorithm most frequently yielding the best
HTP result for each patient model individually: SAR10g,max = (110.3 ± 22.1) W/kg, median
Cancers 2021, 13, 1867 11 of 20
= 114.4 W/kg; SAF = 3.3 ± 0.6, median = 3.3; TCSAR>Lim = (77.1 ± 14.0)%, median = 76.5%;
THQ = 1.4 ± 0.2, median = 1.4 > 1; PTV/VTV = (49.4 ± 8.7) W/L, median = 49.1 W/L >> 30
W/L.
3.2. RF Applicator Comparison: Number of Transmit Channels
With this part of the multi-model study, we aimed to draw a conclusion on the best
suited RF applicator configurations with regard to the number of individual transmit
elements and the head coverage along the cranial–caudal direction. Our preliminary
findings (Pat Model 1) indicated that the planar designs (*.P.*) of the applicator provided
insufficient degrees of freedom for field shaping, while the high density RF arrays (32.2R.*)
underperformed. Extending our quantitative analysis to the Pat Models 2 and 3, these
preliminary findings were confirmed when using the previously employed VOP power
optimization (top row in Figure 5). However, for the MVFS optimization (bottom row in
Figure 5), the outcome was not as conclusive. While the planar arrangements (orange lines)
still clearly underperformed, the high density RF arrays (red lines) underperformed in
Pat Model 1 but outperform all others clearly in Pat Model 2 and slightly in Pat Model
3, allowing for no definitive conclusion at this point. Comparing the 32.2R.* HTP results
with the best results obtained with a 16.* RF applicator design for the most relevant metric
PTV/VTV, the drop when moving from 32.2R.* to 16.2R.* was only −5.5% and −8.3% for
Pat Models 2 and 3, respectively. In both cases, PTV/VTV stayed above our goal of 30 W/L
(PTV/VTV = 37.8 W/L for Pat Model 2 and PTV/VTV = 48.7 W/L for Pat Model 3). Given
the great amount of engineering, manufacturing, and operating effort of the 32 channel RF
arrays and power supply together with the modest results obtained for Pat Models 1 and 3
using the 32.2R.* designs, our further analysis focused on the 16 channels interleaved and
two row designs (16.I.*/16.2R.*).




Figure 5. Influence of the number of independent transmit channels and their arrangement on the TIP results, comparing 
the VOP power optimization and the MVFS optimization. For better comparability, all metrics have been normalized to 
their inter-algorithm, inter-array maximum. Orange: planar arrays, *.P.*; blue: interleaved arrays, 16.I.* and 16.2R.*; red: 
high density arrays 32.2R.*. 
3.3. Hyperthermia Treatment Planning 
For all nine patient models, the four 16 channel designs 16.I.* and 16.2R.* were sim-
ulated and evaluated. For Pat Models 1–5, a water bolus was incorporated in design 
16.I.E.WB. The circular counterpart (16.I.R.WB) was simulated only for Pat Model 1. The 
goal of the thorough comparison of the HTP results was not only to learn about the 
suitability of the RF applicator designs but also to correlate the planning outcome with 
target size and location. For this purpose, the metrics displayed in Figure 6 were nor-
malized to the overall inter-array maximum, making the plots comparable across all pa-
tient models. Please note that normalization to the overall maximum means normalizing 
the SAF to the value achieved using the VOP power optimization. In this figure dis-
playing the results obtained using the MVFS optimization, no result reached maximum 
SAF. 
We repeated our analysis for the mean, standard deviation, and median for all met-
rics when only taking the 16.* RF applicator designs into account: SAR10g,max = (104.4 ± 
24.4) W/kg, median = 104.3 W/kg; SAF = 3.1 ± 0.6, median = 3.3; TCSAR>Lim = (75.9 ± 12.7)%, 
median = 76.5%; THQ = 1.4 ± 0.2, median = 1.3 > 1; PTV/VTV = (48.7 ± 8.9) W/L, median = 
48.7 W/L >> 30 W/L. 
The HTP results for Pat Model 1 improved steadily through the iterations of the 
applicator design development; solely adding the water bolus did not improve the plan-
ning outcome. With PTV/VTV = 66.8 W/L, the overall highest power density could be 
achieved in this very large TV using Design 16.2R.E for this patient model. For Pat Model 
2, a significant improvement was found when moving from the interleaved designs 16.I.* 
to the two row arrangements 16.2R.*. This tendency persists throughout all patient 
models with either Design 16.2R.R or 16.2R.E showing the overall best performance. This 
is particularly interesting for the split target volume in Pat Model 5, where Design 
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3.3. Hyperthermia Treatment Planning
For all nine patient models, the four 16 channel designs 16.I.* and 16.2R.* were sim-
ulated and evaluated. For Pat Models 1–5, a water bolus was incorporated in design
16.I.E.WB. The circular counterpart (16.I.R.WB) was simulated only for Pat Model 1. The
goal of the thorough comparison of the HTP results was not only to learn about the suit-
ability of the RF applicator designs but also to correlate the planning outcome with target
size and location. For this purpose, the metrics displayed in Figure 6 were normalized to
the overall inter-array maximum, making the plots comparable across all patient models.
Please note that normalization to the overall maximum means normalizing the SAF to the
value achieved using the VOP power optimization. In this figure displaying the results
obtained using the MVFS optimization, no result reached maximum SAF.
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We repeated our analysis for the mean, standard deviation, and median for all metrics
when only taking the 16.* RF applicator designs into account: SAR10g,max = (104.4 ± 24.4)
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W/kg, median = 104.3 W/kg; SAF = 3.1 ± 0.6, median = 3.3; TCSAR>Lim = (75.9 ± 12.7)%,
median = 76.5%; THQ = 1.4 ± 0.2, median = 1.3 > 1; PTV/VTV = (48.7 ± 8.9) W/L, median
= 48.7 W/L >> 30 W/L.
The HTP results for Pat Model 1 improved steadily through the iterations of the
applicator design development; solely adding the water bolus did not improve the planning
outcome. With PTV/VTV = 66.8 W/L, the overall highest power density could be achieved
in this very large TV using Design 16.2R.E for this patient model. For Pat Model 2, a
significant improvement was found when moving from the interleaved designs 16.I.* to the
two row arrangements 16.2R.*. This tendency persists throughout all patient models with
either Design 16.2R.R or 16.2R.E showing the overall best performance. This is particularly
interesting for the split target volume in Pat Model 5, where Design 16.2R.R was the only
design supporting RF focusing on both targets simultaneously, allowing treatment of both
tumor locations in a single session. The resulting SAR10g distributions obtained for designs
16.I.R, 16.I.E, 16.I.E.WB, and 16.2R.R were depicted as maximum intensity projections in
Figure 7. The overall highest SAR10g,max(TV) = 143.9 W/kg was obtained in Pat Model 6,
a large superficial post-operative target. This could in part be explained by the slightly
higher conductivity of blood vs. tumor. For the same model, the overall highest SAF of 5.8
was achieved by using the VOP power optimization and Design 16.2R.R. The highest SAF
obtained using the MVFS optimization was 4.12 using Design 16.I.R for the same patient
model. The HTP for Pat Model 7 attained both the highest THQ = 1.64 and the best target
coverage among these designs with TCSAR>Lim = 95.8%. The overall best coverage of 96.9%
was achieved using Design 32.2R.R for Pat Model 3.




Figure 7. Maximum intensity projections of the SAR10g distribution in Patient Model 5 obtained using the MVFS optimi-
zation with designs 16.I.R, 16.I.E, 16.2R.R, and 16.I.E.WB. These RF exposure patterns were achieved by the cumulative 
exposure of 3/3/3/2 excitation settings to be played out in a time-interleaved manner. Design 16.2R.R supports successful 
treatment planning of both sub-TVs with a single optimization run, enabling HT of both sub-TVs in a single session rather 
than two separate sessions requiring full cooling of the brain for accurate treatment prediction. 
4. Discussion 
This study carefully examined the applicability of RF applicator configurations and 
optimization algorithms for patient specific planning of targeted RF power deposition in 
the brain for a diverse set of realistic target volumes derived from GBM patient data. Our 
EMF simulations revealed the insufficient performance of the VOP uniformity optimiza-
tion. MVFS optimization outperformed the VOP power optimization with the exception of 
SAF. This indicates that the better HTP results obtained with MVFS optimization results in 
higher average RF exposure in healthy tissue, by enabling a better RF distribution in the 
healthy tissue and thus a higher RF exposure of the TV. Since all optimization algorithms 
are constrained to the same local safe exposure limits in the healthy tissue, this is of minor 
impact considering the significant improvement of all other treatment metrics. The use of 
the MVFS optimization is thus recommended over VOP uniformity optimization and VOP 
power optimization, as hypothesized at the beginning of this study. Total power deposi-
tion inside healthy tissues could be included in the constraints as well. Our results were 
all obtained using a flat target exposure profile of 100 W/kg in the TV. Since the algorithm 
actually supports weighing of different regions by using inhomogeneous profiles [19], our 
work does not leverage the full potential of the algorithm, leaving room for further im-
provement by patient-specific TV definition, including areas subject to a boosted exposure, 
such as macroscopic tumor growth vs. margin used in the definition of the clinical target 
volume. 
Comparison of our optimization algorithms to existing optimization algorithms 
from the literature was performed vs. an SAF optimization algorithm developed for TVs 
in the brain [33] and the FOCO algorithm developed for TVs in the head and neck region 
[34]. For our intents and purposes, the MVFS algorithm clearly outperformed the SAF 
optimization in all metrics but the SAF and performed at least as well if not better than 
the FOCO algorithm [19,65]. 
All results demonstrate a clear inferiority of the planar array designs 8.P.R and 
16.P.R, as expected. Including the MVFS optimization algorithm into the evaluation of 
the number of independent transmit elements best suited for HT of GBM showed that the 
high density arrays perform better than assumed in the design of this study [16] and are 
superior to the 16 channel counterparts. These results were questioned by the data de-
rived from VOP power optimization comparing all designs for Pat Models 1–3, which 
showed no superiority of the high density arrays 32.2R.*. Weighing the significant in-
crease in engineering and manufacturing efforts required to set-up the high density 32 
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mization with designs 16.I.R, 16.I.E, 16.2R.R, and 16.I.E.WB. These RF exposure patterns were achieved by the cumulative
exposure of 3/3/3/2 excitation settings to be played out in a time-interleaved manner. Design 16.2R.R supports successful
treatment planning of both sub-TVs with a single optimization run, enabling HT of both sub-TVs in a single session rather
than two separate sessions requiring full cooling of the brain for accurate treatment prediction.
4. Discussion
This study carefully examined the applicability of RF applicator configurations and
optimization algorithms for patient specific planning of targeted RF power deposition in
the brain for a diverse set of realistic target volumes derived from GBM patient data. Our
EMF simulations revealed the insufficient performance of the VOP uniformity optimization.
MVFS optimization outperformed the VOP power optimization with the exception of SAF.
This indicate that the better HTP results obtained with MVFS optimizatio results in
higher average RF exposure in healthy tissue, by enabling a better RF distribution in the
healthy tissue and thus a higher RF exposure of the TV. Since all optimization algorithms
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are constrained to the same local safe exposure limits in the healthy tissue, this is of
minor impact considering the significant improvement of all other treatment metrics. The
use of the MVFS optimization is thus recommended over VOP uniformity optimization
and VOP power optimization, as hypothesized at the beginning of this study. Total
power deposition inside healthy tissues could be included in the constraints as well. Our
results were all obtained using a flat target exposure profile of 100 W/kg in the TV. Since
the algorithm actually supports weighing of different regions by using inhomogeneous
profiles [19], our work does not leverage the full potential of the algorithm, leaving room
for further improvement by patient-specific TV definition, including areas subject to a
boosted exposure, such as macroscopic tumor growth vs. margin used in the definition of
the clinical target volume.
Comparison of our optimization algorithms to existing optimization algorithms from
the literature was performed vs. an SAF optimization algorithm developed for TVs in the
brain [33] and the FOCO algorithm developed for TVs in the head and neck region [34]. For
our intents and purposes, the MVFS algorithm clearly outperformed the SAF optimization
in all metrics but the SAF and performed at least as well if not better than the FOCO
algorithm [19,65].
All results demonstrate a clear inferiority of the planar array designs 8.P.R and 16.P.R,
as expected. Including the MVFS optimization algorithm into the evaluation of the number
of independent transmit elements best suited for HT of GBM showed that the high density
arrays perform better than assumed in the design of this study [16] and are superior to
the 16 channel counterparts. These results were questioned by the data derived from VOP
power optimization comparing all designs for Pat Models 1–3, which showed no superiority
of the high density arrays 32.2R.*. Weighing the significant increase in engineering and
manufacturing efforts required to set-up the high density 32 channel RF applicator against
the insignificant changes in HTP outcome would lower the priority of an RF applicator
design equipped with 32 transmit elements. To make ultimate conclusions and to define
the priority on the number of independent transmit elements, further research is warranted
involving a larger cohort of GBM patients. Regardless of the conclusion drawn on the RF
applicator design, this finding also emphasizes the importance of a good HTP algorithm,
leaving the potential of a better treatment outcome untapped otherwise.
Considering head coverage along the head–feet direction, the two row configurations
16.2R.* outperformed the versions with less cranial–caudal coverage, including the inter-
leaved configuration 16.I.*. The enhanced head coverage of the 16.2R.* configurations was
expected to benefit TVs with a large extent in the cranial–caudal direction (Pat Models 1,
6, and 8). While the expectations were met for Pat Models 1 and 6, no HTP improvement
was obtained for Pat Model 8. This was contrasted by HTP improvements in the small
Pat Models 2 and 5. Pat Model 4, however, showed again no HTP improvement despite
almost equaling Pat Model 2 in volume. The commonality between Pat Model 4 and Pat
Model 8, both with comparatively poor HTP outcomes, is the imbalance between the axial
and radial extent of the TV. For the small TV of Pat Model 4, this can be easily understood
by analyzing the RF power deposition pattern of an APA-applicator using λ/2 dipole
antennas, where the field maximum extends along the long axis of the antenna. Even the
two row arrangements of RF applicator models *.2R.* do not support sufficient focusing
in the cranial–caudal direction to confine the SAR maximum to the small extent of the TV.
For Pat Model 8 with a comparatively large extent in the cranial–caudal direction (≈2/3 λ),
we expected better results given the nature of our HTP. With an optimization algorithm
tailored for time-multiplexed RF exposure using multiple phase and amplitude settings
at a rather small wavelength, our approach affords a successful cumulative RF exposure
by sweeping a large TV with multiple separate maxima. Our results, however, suggest
that TVs with a large imbalance between the axial and the radial extent remain challenging
for HTP. This motivates further research into the feature of using multiple RF frequencies
HTP since the MVFS algorithm adapts the main frequency based on the TV size [19]. For
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single frequency HTP, however, this comparison of TV dimensions could a priori indicate
successful HTP and thus serve as an inclusion criterion for patient eligibility.
In addition, the TV location rather than the TV size might add to a better performance
of the two row arrays for small TVs. The TV in Pat Models 2 and 5 are located directly
underneath the skullcap. Since the dipole antenna building blocks are equally distributed
in the axial plane to ensure transmission uniformity in MRI, no dipole elements are placed
directly above the TV. Radiating the RF energy from a steeper angle rather than parallel
to the skullcap seems to have a positive impact on the enhanced performance of the two
row 16.2R.* RF applicator configuration. To test this hypothesis, simulations with the
interleaved 16.I.* designs shifted in the caudal direction could provide further insights.
However, design 16.2R.R afforded successful HTP of a split GBM TV (Pat Mod 5) and
enabled treatment in a single session rather than two separate applications separated by a
cooling period—which supports the applicability and efficacy of this design. Additionally,
deep seated TVs (for example Pat Models 3 and 9) are favored because all RF elements can
contribute almost equally to the RF exposure in the TV.
Using a circular versus an elliptical arrangement of dipole building blocks might have
an impact on HT efficacy. The elliptical design proved superior to the circular arrangement
for Pat Models 1, 2, 4, 7, and 9. This finding did not hold true for Pat Models 3, 5, 6, and 8.
This indicates that a one-size-fits-all RF applicator might not be the ultimate solution for
patient-specific HTP of brain tumors. This approach is commonly and successfully used in
many RF applicators targeting other regions of the body using the APA technique [30,32,38].
These applications outside of the brain however always rely on patient feedback during
treatment to detect and respond to local hot spots and patient discomfort [66–68]. Due to
the lack of pain sensation in the brain [69], the same feedback approach is not feasible for
HT of brain tumors. HT planning and prediction should thus be as precise as possible
with as little trade-off for engineering or other reasons as possible, potentially requiring
a decision between a circular or elliptical design on a patient-to-patient basis. This is in
alignment with reports on choosing the position of the RF antennas within the RF array on
a patient-to-patient basis for microwave HT of brain tumors [70].
This study demonstrated the value and power of numerical simulations and opti-
mization algorithms for HTP in the brain. It is a recognized limitation of the study that
(patho)physiological heat transport mechanisms including blood perfusion or thermo-
regulatory mechanisms were not included in the simulations. Relying on the RF power
deposition in tissue as measured by the SAR is very well established due to the high level
of potential inaccuracies in thermal simulations in the body. However, using SAR instead
of temperature might be viewed as a limitation of our study.
En route to careful validation of our simulations with experiments, we have developed
an anthropomorphic head phantom, which mimics healthy brain tissue and brain tumor
tissue [71]. To implement the experimental setup required for the validation, our group
is currently advancing the installation of a high RF power transmit chain at our 7 T MRI
system. We have already successfully implemented a transmit/receive switch supporting
high average power for RF heating as well as very low power signals for MR imaging [41], a
32 channel RF signal generator tailored to ThermalMR [27], and an RF supervision module
for phase and power monitoring [72]. We are very much looking forward to performing
RF heating experiments with a high channel count.
5. Conclusions
This work elucidated the efficacy of planar and three-dimensional RF applicator
configurations in conjunction with RF field shaping optimization for patient specific HTP
in GBM target volumes. Our results demonstrate that for each patient model, HTP could
be successfully performed, and an optimization algorithm for further use was identified.
Minimum requirements formulated for the metrics investigated were met and exceeded
for all patient specific cases.
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To summarize, our findings add to the literature by underlining that a one-size-fits-all
RF applicator is not the ultimate approach for HT of brain tumors. While a two row RF
applicator arrangement provided best performance, it stands to reason that modular and
reconfigurable RF applicator configurations might best suit the needs of targeting individ-
ual GBM geometry. To conclude, this research provides important data for patient specific
HTP, with the emphasis on a sophisticated HTP algorithm, and forms a technological basis
for future development of RF applicators tailored for ThermalMR applications in the brain.
Our simulations are a mandatory precursor of broader experiments that are tailored to
evaluate and validate RF applicator configurations en route to clinical application.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13081867/s1, Table S1: Full VOP power optimization HTP results, Table S2: Full VOP
uniformity optimization HTP results, Table S3: Full MVFS optimization HTP results.
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Appendix A
Table 1. Segmented target volumes and organs at risk with their assigned tissue types and dielectric properties for EMF
simulations. Dielectric properties of healthy tissue were taken from the IT’IS database [48,49]. Solid tumor tissue was
assigned the average of two values reported from the only in vivo measurement known to the authors [47]. Some organs
and tissues were delineated for all patient models, while specific organs at risk were selected based on the individual
location of the target volume. * Upon further discussion throughout the patient model creation, changes in the assigned
dielectric properties were made, for example addressing the fact that cavities in the human head are typically not empty
and should thus not be simulated as pure air. Comparison studies were performed (data not shown here) and showed no
significant influence, even for the fairly large difference in conductivity and relative permittivity in the cavities. This is
most likely due to the small geometrical extent and the comparatively large SAR averaging volume. ** The manual organ
contouring sometimes generated residual voxels not assigned to any specific organ. These voxels were assigned averaged
properties of muscle and fat.





Brain 40% WM + 60% GM 0.52 50.3
Brainstem 40% WM + 60% GM 0.52 50.3
Eye Vitreous humor 1.52 69
Optical nerve Nerve 0.42 37
Chiasm * White matter 0.42 43.8
Spinal cord Nerve 0.42 37
Ventricles CSF 2.22 72.8
External CSF CSF 2.22 72.8
Fat Fat 0.07 11.7
Muscle Muscle 0.77 58.2
Skull Bone 0.08 13.5
Cavities * Lung (inflated) 0.36 24.8
Pat Model 1
Tumor growth Tumor 1.15 66.5
Vessels Blood 1.32 65.7
Pituitary gland Hypothalamus 0.69 60.1
Hypothalamus Hypothalamus 0.69 60.1
Chiasm * Nerve 0.42 37
Cavities * Air 0 1
Pat Model 2
Resection cavity Blood 1.32 65.7
Body ** 50% Muscle + 50% Fat 0.42 35
Hypothalamus Hypothalamus 0.69 60.1
Blood vessels Blood 1.32 65.7
Pat Model 3
Tumor growth (solid) Tumor 1.15 66.5
Tumor growth (non-solid) Tumor 1.15 66.5
Body 50% Muscle + 50% Fat 0.54 42.7
Hypothalamus Hypothalamus 0.69 60.1
Blood vessels Blood 1.32 65.7
Pat Model 4
Tumor growth Tumor 1.15 66.5
Trepanation Skin 0.64 49.9
Hypophysis Hypophysis 0.85 62.5
Inner ear 60% Cartilage + 30% bone + 5% cavity + 5% muscle 0.45 39.2
Pat Model 5
Tumor growth Tumor 1.15 66.5
Inner ear 60% Cartilage + 30% bone + 5% cavity + 5% muscle 0.45 39.2
Hippocampus Hippocampus 0.69 60.1
Lacrimalis Thyroid Gland 0.85 62.9
Cerebellum 40% WM + 60% GM 0.52 50.3
Pat Model 6
Resection cavity Blood 1.32 65.7
Inner ear 60% Cartilage + 30% bone + 5% cavity + 5% muscle 0.45 39.2
Pat Model 7
Tumor growth Tumor 1.15 66.5
Inner ear 60% Cartilage + 30% bone + 5% cavity + 5% muscle 0.45 39.2
Hypophysis Hypophysis 0.85 62.5
Pat Model 8
Tumor growth Tumor 1.15 66.5
Pituitary gland Hypophysis 0.85 62.5
Inner ear 60% Cartilage + 30% bone + 5% cavity + 5% muscle 0.45 39.2
Pat Model 9
Tumor growth Tumor 1.15 66.5
Inner ear 60% Cartilage + 30% bone + 5% cavity + 5% muscle 0.45 39.2
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